Aspirin induces immunogenic cell death and enhances cancer immunotherapy in colorectal cancer

Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8 Horn, 2017, Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057), J. Clin Oncol. Official J. Am. Soc. Clin. Oncol., 35, 3924, 10.1200/JCO.2017.74.3062 Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet (London, England), 390, 2461, 10.1016/S0140-6736(17)31827-5 Fucikova, 2011, Human tumor cells killed by anthracyclines induce a tumor-specific immune response, Cancer Res., 71, 4821, 10.1158/0008-5472.CAN-11-0950 Wang, 2022, Current therapy and development of therapeutic agents for lung cancer, Cell Insight, 1, 10.1016/j.cellin.2022.100015 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science (New York, NY), 348, 124, 10.1126/science.aaa1348 Schumacher, 2015, Neoantigens in cancer immunotherapy, Science (New York, N.Y.), 348, 69, 10.1126/science.aaa4971 Haanen, 2017, Converting cold into hot tumors by combining immunotherapies, Cell, 170, 1055, 10.1016/j.cell.2017.08.031 Bai, 2021, Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy, Oncoimmunology, 10, 1868130, 10.1080/2162402X.2020.1868130 Bai, 2021, Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation, Sci. China Life Sci., 64, 2144, 10.1007/s11427-020-1888-1 Casares, 2005, Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J. Exp. Med., 202, 1691, 10.1084/jem.20050915 Obeid, 2007, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat. Med., 13, 54, 10.1038/nm1523 Tesniere, 2010, Immunogenic death of colon cancer cells treated with oxaliplatin, Oncogene, 29, 482, 10.1038/onc.2009.356 Krysko, 2012, Immunogenic cell death and DAMPs in cancer therapy, Nat. Rev. Cancer, 12, 860, 10.1038/nrc3380 Massé, 2004, Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy, Int. J. Cancer, 111, 575, 10.1002/ijc.20249 Apetoh, 2007, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat. Med., 13, 1050, 10.1038/nm1622 Siegel, 2019, Cancer Statis. 2019, 69, 7 Drew, 2016, Aspirin and colorectal cancer: the promise of precision chemoprevention, Nat. Rev. Cancer, 16, 173, 10.1038/nrc.2016.4 Keller, 2003, Chemoprevention strategies using NSAIDs and COX-2 inhibitors, Cancer Biol. Ther., 2, S140 Figueiredo, 2021, Associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with colorectal cancer mortality after diagnosis, J. Natl. Cancer Inst., 10.1093/jnci/djab008 Guo, 2021, Aspirin use and risk of colorectal cancer among older adults, JAMA Oncol., 7, 428, 10.1001/jamaoncol.2020.7338 Burn, 2011, Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial, Lancet (London, England), 378, 2081, 10.1016/S0140-6736(11)61049-0 Burn, 2020, Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial, Lancet (London, England), 395, 1855, 10.1016/S0140-6736(20)30366-4 Kepp, 2013, Crosstalk between ER stress and immunogenic cell death, Cytokine Growth Factor Rev., 24, 311, 10.1016/j.cytogfr.2013.05.001 Radogna, 2018, Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy, Biochem. Pharmacol., 153, 12, 10.1016/j.bcp.2018.02.006 Vishnu, 2014, ATP increases within the lumen of the endoplasmic reticulum upon intracellular Ca2+ release, Mol. Biol. Cell, 25, 368, 10.1091/mbc.e13-07-0433 Dang, 2009, MYC-induced cancer cell energy metabolism and therapeutic opportunities, Clin. Cancer Res., 15, 6479, 10.1158/1078-0432.CCR-09-0889 Tateishi, 2016, Myc-driven glycolysis is a therapeutic target in glioblastoma, Clin. Cancer Res., 22, 4452, 10.1158/1078-0432.CCR-15-2274 Dang, 2013, MYC, metabolism, cell growth, and tumorigenesis, Cold Spring Harb. Perspect. Med., 3, 10.1101/cshperspect.a014217 Sagar, 2019, EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells, Cell Death Dis., 10, 801, 10.1038/s41419-019-2042-y Peng, 2015, Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer, Cancer Res., 75, 5034, 10.1158/0008-5472.CAN-14-3098 Huang, 1996, The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product, PNAS, 93, 9730, 10.1073/pnas.93.18.9730 Slansky, 2000, Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex, Immunity, 13, 529, 10.1016/S1074-7613(00)00052-2 Jordan, 2010, Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens, PNAS, 107, 4652, 10.1073/pnas.0914879107 Wei, 2021, Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer, Proc. Nat. Acad. Sci. United States America, 118, 7, 10.1073/pnas.2100588118 Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107 Yatim, 2017, Dying cells actively regulate adaptive immune responses, Nat. Rev. Immunol., 17, 262, 10.1038/nri.2017.9 Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu. Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008 Galluzzi, 2020, Consensus guidelines for the definition, detection and interpretation of immunogenic cell death, J. Immunother. Cancer, 8, 10.1136/jitc-2019-000337 Kono, 2008, How dying cells alert the immune system to danger, Nat. Rev. Immunol., 8, 279, 10.1038/nri2215 Kepp, 2014, Consensus guidelines for the detection of immunogenic cell death, Oncoimmunology, 3, e955691, 10.4161/21624011.2014.955691 Verfaillie, 2013, Targeting ER stress induced apoptosis and inflammation in cancer, Cancer Lett., 332, 249, 10.1016/j.canlet.2010.07.016 Schröder, 2008, Endoplasmic reticulum stress responses, Cell. Mol. Life Sci., 65, 862, 10.1007/s00018-007-7383-5 Naidoo, 2009, ER and aging-protein folding and the ER stress response, Age. Res. Rev., 8, 150, 10.1016/j.arr.2009.03.001 Banerjee, 2012, N-glycans in cell survival and death: cross-talk between glycosyltransferases, BBA, 1820, 1338 van der Harg, 2017, The UPR reduces glucose metabolism via IRE1 signaling, Biochim. Biophys. Acta, 1864, 655, 10.1016/j.bbamcr.2017.01.009